Biomx Inc
PHGE0.422USD
+0.025+6.41%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
10.53MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Biomx Inc Unternehmen
BiomX Inc., formerly Chardan Healthcare Acquisition Corp., is a microbiome company. The Company is focused on developing both natural and engineered phage therapies. It develops therapies to target and destroy bacteria that affect the appearance of skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease (IBD), primary sclerosing cholangitis (PSC) and cancer. The Company discovers and validates bacterial targets and customizes phage compositions against the targets. Its pipeline includes BX001, BX002 and BX003. BX001 is a product candidate that improves the appearance of acne-prone skin. BX002 is a customized phage cocktail that eradicates bacterial targets associated with the onset of IBD. BX003 is a customized phage cocktail developed against specific strains of Klebsiella pneumoniae (Kp).
Unternehmensinformationen
BörsenkürzelPHGE
Name des UnternehmensBiomx Inc
IPO-datumDec 18, 2018
CEOMr. Jonathan Eitan Solomon
Anzahl der mitarbeiter52
WertpapierartOrdinary Share
GeschäftsjahresendeDec 18
Addresse22 Einstein St.
StadtNESS-ZIONA
BörseNYSE American Consolidated
LandIsrael
Postleitzahl7414003
Telefon972723942377
Websitehttps://www.biomx.com/
BörsenkürzelPHGE
IPO-datumDec 18, 2018
CEOMr. Jonathan Eitan Solomon
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Jonathan Eitan Solomon
Mr. Jonathan Eitan Solomon
Chief Executive Officer, Director
Chief Executive Officer, Director
179.80K
+238.89%
Ms. Marina Wolfson, CPA
Ms. Marina Wolfson, CPA
Chief Financial Officer
Chief Financial Officer
68.92K
+18278.67%
Mr. Assaf Oron
Mr. Assaf Oron
Chief Business Officer
Chief Business Officer
25.80K
--
Ms. Susan Blum, CPA
Ms. Susan Blum, CPA
Independent Director
Independent Director
--
--
Mr. Michael Dambach
Mr. Michael Dambach
Independent Director
Independent Director
--
--
Mr. Jonathan S. Leff
Mr. Jonathan S. Leff
Director
Director
--
--
Dr. Alan Charles Moses, M.D.
Dr. Alan Charles Moses, M.D.
Independent Director
Independent Director
--
--
Dr. Jesse Goodman, M.D.
Dr. Jesse Goodman, M.D.
Director
Director
--
--
Ms. Anat Primovich
Ms. Anat Primovich
Corporate Project Manager
Corporate Project Manager
--
--
Mr. Jason Marks
Mr. Jason Marks
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Jonathan Eitan Solomon
Mr. Jonathan Eitan Solomon
Chief Executive Officer, Director
Chief Executive Officer, Director
179.80K
+238.89%
Ms. Marina Wolfson, CPA
Ms. Marina Wolfson, CPA
Chief Financial Officer
Chief Financial Officer
68.92K
+18278.67%
Mr. Assaf Oron
Mr. Assaf Oron
Chief Business Officer
Chief Business Officer
25.80K
--
Ms. Susan Blum, CPA
Ms. Susan Blum, CPA
Independent Director
Independent Director
--
--
Mr. Michael Dambach
Mr. Michael Dambach
Independent Director
Independent Director
--
--
Mr. Jonathan S. Leff
Mr. Jonathan S. Leff
Director
Director
--
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Wed, Jun 25
Aktualisiert: Wed, Jun 25
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Deerfield Management Company, L.P.
9.53%
Cystic Fibrosis Foundation
9.53%
Nantahala Capital Management, LLC
9.53%
Alyeska Investment Group, L.P.
6.08%
AIGH Capital Management, LLC.
4.52%
Other
60.82%
Aktionäre
Aktionäre
Anteil
Deerfield Management Company, L.P.
9.53%
Cystic Fibrosis Foundation
9.53%
Nantahala Capital Management, LLC
9.53%
Alyeska Investment Group, L.P.
6.08%
AIGH Capital Management, LLC.
4.52%
Other
60.82%
Aktionärstypen
Aktionäre
Anteil
Hedge Fund
31.66%
Corporation
13.62%
Private Equity
4.52%
Holding Company
4.09%
Investment Advisor
3.77%
Venture Capital
3.72%
Investment Advisor/Hedge Fund
2.37%
Research Firm
1.65%
Individual Investor
1.48%
Other
33.12%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
47
17.51M
66.88%
+4.34M
2025Q1
47
17.95M
68.92%
+5.32M
2024Q4
47
13.90M
76.65%
+2.77M
2024Q3
43
13.00M
74.85%
+8.58M
2024Q2
33
4.45M
66.70%
+1.05M
2024Q1
34
2.97M
56.90%
+586.97K
2023Q4
35
2.25M
51.72%
+502.58K
2023Q3
39
1.91M
46.61%
-56.19K
2023Q2
39
1.94M
47.21%
+273.60K
2023Q1
38
1.06M
33.47%
-530.41K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Deerfield Management Company, L.P.
2.49M
9.53%
+1.25M
+100.00%
Mar 31, 2025
Cystic Fibrosis Foundation
2.49M
9.53%
+706.35K
+39.51%
Feb 27, 2025
Nantahala Capital Management, LLC
2.49M
9.53%
+762.71K
+44.07%
Mar 31, 2025
Alyeska Investment Group, L.P.
1.59M
6.08%
+725.34K
+83.82%
Mar 31, 2025
AIGH Capital Management, LLC.
1.18M
4.52%
+533.12K
+82.04%
Mar 31, 2025
Centaurus Investments Limited
1.07M
4.09%
+1.07M
--
Apr 21, 2025
Allostery Investments LP
940.63K
3.59%
+296.80K
+46.10%
Mar 31, 2025
Ikarian Capital LLC
892.98K
3.41%
--
--
Mar 31, 2025
AMR Action Fund LP
876.89K
3.35%
+571.40K
+187.05%
Sep 30, 2024
Telmina Ltd
560.27K
2.14%
+276.30K
+97.30%
Sep 30, 2024
Mehr Anzeigen
Verbundene ETFs
Name
Anteil
Keine Daten
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Aug 15, 2024
Merger
10<1
Aug 15, 2024
Merger
10<1
Aug 15, 2024
Merger
10<1
Aug 15, 2024
Merger
10<1
Datum
Art
Verhältnis
Aug 15, 2024
Merger
10<1
Aug 15, 2024
Merger
10<1
Aug 15, 2024
Merger
10<1
Aug 15, 2024
Merger
10<1
